Skip to main content

Table 2 Multivariate analysis of overall survival for Bcl-2 expression in lung cancer patients of the validation cohort

From: High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology

 

Validation Cohort

 

All patients

Non squamous

Characteristic

HR (95% CI)

p value*

HR (95% CI)

p value*

Age

1.02 (1-1.04)

0.02

1.03 (1-1.06)

0.04

Gender

    

Female

1

   

Male

0.72 (0.44-1.18)

0.19

0.6 (0.29-1.24)

0.17

Stage

    

Stage I

1

 

1

 

Stage II

1.9 (1.18-3)

0.008

2.2 (1.07-4.54)

0.03

Stage III

3 (1.9-4.6)

< 0.001

3.6 (1.8-7.1)

< 0.001

Stage IV

4.1 (2.4-7.02)

< 0.001

5.1 (2.5-10.49)

< 0.001

Histology

    

Adenocarcinoma

1

   

Squamous cell carcinoma

1.1 (0.76-1.6)

0.6

  

Large cell carcinoma

0.8 (0.19-3.46)

0.8

  

Adenosquamous carcinoma

0.9 (0.21-3.77)

0.9

  

Giant cell carcinoma

1.05 (0.46-2.41)

0.9

  

Various

1.5 (0.6-3.97)

0.4

  

Differentiation

    

High

1

 

1

 

Moderate

2.1 (0.99-4.6)

0.05

3.01 (1.14-7.89)

0.025

Low

1.4 (0.67-3.03)

0.3

1.38 (0.52-3.67)

0.5

Bcl-2

    

Low

1

 

1

 

High

0.53 (0.37-0.75)

0.0003

0.5 (0.31-0.81)

0.005

  1. *p is given for Cox multivariate analysis, statistically significant p values (p < 0.05) are in boldface, trending p values in italics, HR; hazard ratio
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us